Actively Recruiting
Evaluation of 64Cu-DOTA-ECL1i PET Imaging in Head and Neck Squamous Cell Carcinoma Patients Before Surgery or Anti-PD1 Therapy
Led by Washington University School of Medicine · Updated on 2026-10-07
90
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of a novel PET imaging tracer called 64Cu-DOTA-ECL1i to improve precision imaging for patients with head and neck squamous cell carcinoma HNSCC. This phase 2 study aims to assess how well this imaging technique detects cancer presence and activity, focusing on both newly diagnosed and recurrent or metastatic cases. Participants are divided into two groups Cohort 1 includes patients with newly diagnosed locally advanced HNSCC scheduled for surgery, who will undergo one 64Cu-DOTA-ECL1i PETCT scan before surgery and any neoadjuvant therapy. Cohort 2 consists of patients with recurrent or metastatic HNSCC receiving first-line anti-PD1 therapy, who will have two PET scansone before starting therapy and another after three treatment cycles. The tracer is given intravenously, followed by a saline flush. During the study, participants will be monitored for adverse effects through phone or in-person follow-ups within 24 hours to 14 days after tracer administration. Clinical and radiological appointments will be reviewed as part of standard care. Researchers will measure PET tracer uptake both semiquantitatively and quantitatively at baseline and surgery, assess CCR2 expression in tumor tissue, and evaluate outcomes such as response to therapy, progression-free survival, and overall survival for Cohort 2. The total study period extends up to 12 months for some measures, with study completion planned by May 2032.
CONDITIONS
Brief Title
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
Research Team
F
Farrokh Dehdashti, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here